Patents by Inventor John E. DeLeon

John E. DeLeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted anilinic piperidines as MCH selective antagonists
    Patent number: 7067534
    Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: June 27, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Yu Jiang, Chien-An Chen, Kai Lu
  • Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
    Publication number: 20040242609
    Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 15, 2004
    Publication date: December 2, 2004
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Mohammad R. Marzabadi, John Wetzel, John E. Deleon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
  • Substituted anilinic piperidines as MCH selective antagonists
    Patent number: 6727264
    Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: April 27, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Yu Jiang, Chien-An Chen, Kai Lu
  • Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
    Patent number: 6720324
    Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: April 13, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
  • Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
    Publication number: 20030069261
    Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 5, 2001
    Publication date: April 10, 2003
    Inventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam